Hepatitis B e-antigen persistency is associated with the properties of HBV-specific CD8 T cells in CHB patients

Journal of Clinical Immunology

Volumn 31, Issue 2, 2011, Pages 195-204

  Peng, Guoping ^a   Luo, Benyan ^b   Li, Jie ^a   Zhao, Dongjiu ^a   Wu, Wei ^a   Chen, Feng ^a   Chen, Zhi ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

HBV specific T cellular response; Hepatitis B e antigen; histological grades; PD 1; viral load

Indexed keywords

ALANINE AMINOTRANSFERASE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; HEPATITIS B(E) ANTIGEN; PROGRAMMED DEATH 1 RECEPTOR; TRANSCRIPTION FACTOR FOXP3; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; EFFECTOR CELL; FEMALE; HEPATITIS B; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER FIBROSIS; LIVER HISTOLOGY; LIVER NECROSIS; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; VIRUS LOAD;

ADOLESCENT; ADULT; ALANINE TRANSAMINASE; CD8-POSITIVE T-LYMPHOCYTES; DNA, VIRAL; EPITOPES; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; RNA, MESSENGER; T-LYMPHOCYTES, REGULATORY; YOUNG ADULT;

EID: 79959692373     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-010-9483-5     Document Type: Article

References (36)

1. Hsu YS, Chien RN, Yeh CT, Sheen IS, Chiou HY, Chu CM, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology. 2002;35:1522-7.
2. Perrillo RP. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology. 2001;120:1009-22. (Pubitemid 32193199)
3. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2001;34:1225-41. (Pubitemid 33096596)
4. Baumert TF, Liang TJ. Precore mutants revisited. Hepatology. 1996;23:184-6. (Pubitemid 26012108)
5. Milich DR, Chen MK, Hughes JL, Jones JE. The secreted hepatitis B precore antigen can modulate the immune response to the nucleocapsid: a mechanism for persistence. J Immunol. 1998;160:2013-21. (Pubitemid 28106492)
6. Milich DR, Liang TJ. Exploring the biological basis of hepatitis B e antigen in hepatitis B virus infection. Hepatology. 2003;38:1075-86. (Pubitemid 37314815)
7. al-Ramadi BK, Welte T, Fernandez-Cabezudo MJ, Galadari S, Dittel B, Fu XY, et al. The Src-protein tyrosine kinase Lck is required for IL-1-mediated costimulatory signaling in Th2 cells. J Immunol. 2001;167:6827-33.
8. Chen MT, Billaud JN, Sallberg M, Guidotti LG, Chisari FV, Johnes J, et al. A function of the hepatitis B virus precore protein is to regulate the immune response to the core antigen. Proc Natl Acad Sci USA. 2004;101:14913-8. (Pubitemid 39410774)
9. Du H, Li T, Zhang HY, He ZP, Qong QM, Duan XZ, et al. Correlation of hepatitis B virus (HBV) genotypes and mutations in basal core promoter/precore with clinical features of chronic HBV infection. Liver Int. 2007;27:240-6. (Pubitemid 46680729)
10. Fried MW, Piratvisuth T, Lau GK, Marcellin P, Chow WC, Cooksley G, et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology. 2008;47:428-34. (Pubitemid 351280710)
11. Sun HC, Zhang W, Qin LX, Zhang BH, Ye QH, Wang L, et al. Positive serum hepatitis B e antigen is associated with higher risk of early recurrence and poorer survival in patients after curative resection of hepatitis B-related hepatocellular carcinoma. J Hepatol. 2007;47:684-90. (Pubitemid 47503431)
12. Yuen MF, Yuan HJ, Wong DK, Yuen JC, Wong WM, Chan AO, et al. Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut. 2005;54:1610-4. (Pubitemid 41531781)
13. Zavaglia C, Mondazzi L, Maggi G, Iamoni G, Gelosa F, Bellati G, et al. Are alanine aminotransferase, hepatitis B virus DNA or IgM antibody to hepatitis B core antigen serum levels predictors of histological grading in chronic hepatitis B. Liver. 1997;17:83-7. (Pubitemid 27179981)
14. Volz T, Lutgehetmann M, Wachtler P, Jacob A, Quaas A, Murray JM, et al. Impaired intrahepatic hepatitis B virus productivity contributes to low viremia in most HBeAg-negative patients. Gastroenterology. 2007;133:843-52. (Pubitemid 47374140)
15. Lindh M, Horal P, Dhillon AP, Norkrans G. Hepatitis B virus DNA levels, precore mutations, genotypes and histological activity in chronic hepatitis B. J Viral Hepat. 2000;7:258-67.
16. Feld JJ, Ayers M, El-Ashry D, Mazzulli T, Tellier R, Heathcote EJ. Hepatitis B virus DNA prediction rules for hepatitis B e antigen-negative chronic hepatitis B. Hepatology. 2007;46:1057-70. (Pubitemid 350147802)
17. Cabrera R, Tu Z, Xu Y, Firpi RJ, Rosen HR, Liu C, et al. An immunomodulatory role for CD4+ CD25+ regulatory T lymphocytes in hepatitis C virus infection. Hepatology. 2004;40:1062-71. (Pubitemid 39425561)
18. Stoop JN, van der Molen RG, Baan CC, van der Laan LJ, Kuipers EJ, Kusters JG, et al. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology. 2005;41:771-8. (Pubitemid 40462939)
19. Peng G, Li S, Wu W, Sun Z, Chen Y, Chen Z. Circulating CD4+ CD25+ regulatory T cells correlate with chronic hepatitis B infection. Immunology. 2008;123:57-65. (Pubitemid 350255997)
20. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1981;1:4331-5.
21. Tang CL, Chen Z, Peng GP, Yang ZG, Zhou LF. Analysis of differential gene expression between chronic hepatitis B patients and asymptomatic hepatitis B carriers. J Gastroenterol Hepatol. 2006;22:74-9.
22. Chan HL, Hui Y, Leung NW, Ching JY, Chan FK, Sung JJ. Risk factors for active liver disease in HbeAg-negative chronic hepatitis B virus-infected patients. Am J Gastroenterol. 2000;95:3547-51.
23. Maruyama T, Mitsui H, Maekawa H, Yamada H, Hirayama M, Lino S, et al. Emergence of the precore mutations in the core region. Am J Gastroenterol. 2000;95:2890-4.
24. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130:678-86. (Pubitemid 43374518)
25. Guidotti LG, Ishikawa T, Hobbs MV, Matzeke B, Schreiber R, Chisari FV. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity. 1996;4:25-36. (Pubitemid 26054933)
26. Chun Y, Kim JY, Woo H, Oh SM, Kang I, Ha J, et al. No Significant correlation exists between core promoter mutations, viral replication, and liver damage in chronic hepatitis B infection. Hepatology. 2000;32:1154-62.
27. Maini MK, Boni C, Ogg GS, King AS, Reignat S, Lee CK, et al. Direct ex vivo analysis of hepatitis B virus-specific CD8+ T cells associated with the control of infection. Gastroenterology. 1999;117:1386-96.
28. Boni C, Fisicaro P, Valdatta C, Amadei B, Divincenzo P, Giuberti T, et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol. 2007;81:4215-25. (Pubitemid 46586915)
29. Fisicaro P, Valdatta C, Massari M, Loggi E, Biasini E, Sacchelli L, et al. Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology. 2010;138:682-93.
30. Takahashi T, Tagami T, Yamazaki S, Uede T, Shimizu J, Sakaguchi N, et al. Immunologic self-tolerance maintained by CD25+ CD4+ regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med. 2000;192:303-10.
31. Feng IC, Koay LB, Sheu MJ, Kuo HT, Sun CS, Lee C, et al. HBcAg-specific CD4+ CD25+ regulatory T cells modulate immune tolerance and acute exacerbation on the natural history of chronic hepatitis B virus infection. J Biomed Sci. 2007;14:43-57. (Pubitemid 46295275)
32. Yu Y, Wu H, Tang Z, Zang G. CTLA4 silencing with siRNA promotes deviation of Th1/Th2 in chronic hepatitis B patients. Cell Mol Immunol. 2009;6:123-7.
33. Egen JG, Kuhns MS, Allison JP. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol. 2002;3:611-8. (Pubitemid 34752469)
34. Peng G, Li S, Wu W, Tan X, Chen Y, Chen Z. PD-1 upregulation is associated with HBV-specific T cell dysfunction in chronic hepatitis B patients. Mol Immunol. 2008;45:963-70. (Pubitemid 350019503)
35. Currana MA, Montalvoa W, Yagitab H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA. 2010;107:4275-80.
36. Nakamoto N, Cho H, Shaked A, Olthoff K, Valiga ME, Kaminski M, et al. Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade. PLoS Pathog. 2009;5:1-13.